36
Participants
Start Date
March 28, 2008
Primary Completion Date
February 3, 2014
Study Completion Date
February 3, 2014
HDI
20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression
KW2871
5 mg/m\^2 IV every 2 weeks until disease progression
KW2871
10 mg/m\^2 IV every 2 weeks until disease progression
KW2871
20 mg/m\^2 IV every 2 weeks until disease progression
University of Pittsburgh Cancer Institute, Pittsburgh
University of Chicago Hospital, Chicago
Lead Sponsor
Collaborators (1)
University of Pittsburgh
OTHER
University of Chicago
OTHER
Life Science Pharmaceuticals
UNKNOWN
Ludwig Institute for Cancer Research
OTHER